Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
arcticnovartis

  • Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹

  • Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other members of the Board of Directors who stood for re-election; Charles Swanton newly elected as member of the Board of Directors
/by
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
arcticnovartis

  • Die Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹

  • Die Aktionärinnen und Aktionäre bestätigten Giovanni Caforio als Vorsitzenden des Verwaltungsrats sowie alle weiteren Mitglieder des Verwaltungsrats die zur Wiederwahl standen. Charles Swanton wurde zum neuen Mitglied des Verwaltungsrats gewählt.
/by
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
arcticnovartis

  • Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline
  • Potentially unlocks multi-billion-dollar opportunities with planned product launches before 2030
  • Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook

/by
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis

  • Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe
  • Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile including no liver safety concerns through Week 521
/by
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
arcticnovartis

  • Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US
  • Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types
  • Company broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations
/by
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
arcticnovartis

  • In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC
  • Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs
/by
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis

  • Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
  • Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
/by
Breaking ground in Global Health

Breaking ground in Global Health
metzgma4

/by
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis

  • Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
  • Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
/by
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis

  • Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1
  • Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and demonstrated a favorable safety profile, including no liver safety concerns1
  • Oral remibrutinib has potential to be first targeted therapy approved for CIndU, which affects estimated 29 million adults worldwide2,3
/by